Childhood cancer treatments may increase obesity risk later
the ONA take:
According to a new study published online early in the journal Cancer, researchers have found that certain treatments used to treat children with cancer may increase their risk for obesity later in life.
For the study, researchers analyzed data from nearly 2,000 cancer survivors previously treated for their disease at St. Jude Children's Research Hospital in Memphis, Tennessee, who had been diagnosed with cancer at least 10 years ago. Results showed that 47% of survivors who had received cranial radiation were obese versus 29.4% of those who had not received cranial radiation.
Researchers found that patients who were treated with cranial radiation plus glucocorticoids, such as prednisone and dexamethasone, had an increased likelihood of obesity. Patients who were younger at the time of diagnosis also had an increased risk for obesity.
The findings may help health care providers identify cancer survivors who are more likely to become obese and guide treatment selection in order to minimize long-term complications.
Certain treatments used to treat children with cancer may increase their risk for obesity later in life.
- Clinical Trials May Benefit Oncology Patients
- Breast Cancer Overdiagnosis Also a Result of Screening Mammography Programs
- Prostate-specific PET and CT Imaging Improves Detection of Disease and Patient Care
- Cancer Risk Not Increased by Childhood Exposure to Diagnostic Radiation
- Aspirin Use May Lower Breast Cancer Risk in Women with Diabetes
- Survivorship Care Plans: Providing A Blueprint for Health Care After Cancer
- Multifaceted Role of the Nurse Navigator Includes Palliative, Supportive Care
- Cancer Recurrence Fear Reduced by Novel Psychological Intervention
- Immune Thrombocytopenia (Fact Sheet)
- Patient Navigators Found to Boost Lung Cancer Screening Rates
- Novel 3D Marker Reduces Radiation, Improves Cosmesis in Breast Conserving Surgery
- Rates at Some Milestones May Indicate Clinical Trial Results for Immunotherapeutics
- Cancer Risks for BRCA1/2 Mutation Carriers Determined by Age, Family History, Mutation Location
- Long-Term Use of TPO Receptor Agonist Safe in CLL-Associated Immune Thrombocytopenia
- Savolitinib Active, Tolerable in Subset of Advanced Papillary Renal Cell Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|